Anethole trithione
Anethole trithione, anetholtrithione, or anetholtrithion (JAN) is a drug used in the treatment of dry mouth. It is listed in the U.S. National Cancer Institute's Dictionary of Cancer Terms as being studied in the treatment of cancer.[1] Anethole trithione is an organosulfur compound, specifically, a dithiole-thione derivative.
 | |
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.007.754  |
| Chemical and physical data | |
| Formula | C10H8OS3 |
| Molar mass | 240.365 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Brand names
- Felviten
- Halpen
- Hepasulfol - Franco-Indian Pharmaceuticals
- Heporal
- Mucinol - Sanofi-Aventis
- Sialor - Paladin Laboratories; Pharmascience; Solvay; Zuoz Pharma
- Sonicur - Solvay
- Sulfarlem - Solvay; Aguettant; Edward Keller; Sanofi-Aventis
- Sulfarlem S - EG Labo
- Tiopropen
- Tiotrifar
See also
- Anethole
References
- Anetholtrithione entry in the public domain NCI Dictionary of Cancer Terms. Retrieved September 13, 2008.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.